Brenig Therapeutics initiates first-in-human trial of BT-267 for Parkinson's
- Brenig Therapeutics has started a first-in-human clinical trial for BT-267, a LRRK2 inhibitor for Parkinson's disease.
- The trial, which began in November 2024, involves dosing healthy volunteers to assess safety and tolerability.
- Preclinical data shows BT-267 has a superior safety profile with no significant lung or kidney changes at high doses.
- Future proof-of-concept studies are planned for patients with idiopathic Parkinson's disease.
Read more
Anavex Life Sciences announces acceptance of manuscript on blarcamesine for Alzheimer's
- Anavex Life Sciences' manuscript on oral blarcamesine for early Alzheimer's disease has been accepted by a peer-reviewed journal.
- The publication is expected around Q4 2024/Q1 2025, marking a significant milestone for the company.
- Anavex is preparing for regulatory submission of blarcamesine in Europe (EMA) within the current quarter of 2024.
- The manuscript highlights the potential of blarcamesine to educate the medical community about its benefits for Alzheimer's patients.
Read more
IGC Pharma announces additional phase 2 interim results highlighting cognitive benefits of IGC-AD1 for Alzheimer's treatment
- IGC Pharma shared interim data from its Phase 2 trial of IGC-AD1, focusing on agitation in Alzheimer's patients.
- The trial showed cognitive improvements in the active treatment group, with an 8% increase in MMSE scores over six weeks.
- Preclinical data indicated a 20% reduction in amyloid plaque aggregation and a 50% improvement in spatial memory.
- IGC-AD1 demonstrated rapid agitation reduction, with effects seen in two weeks, offering a favorable safety profile.
Read more
MaaT Pharma announces positive phase 1b results for MaaT033 in ALS
- MaaT Pharma's Phase 1b trial of MaaT033 in ALS met its primary endpoint, demonstrating safety and tolerability.
- The trial involved 15 participants across two centers in France, with the DSMB supporting progression to Phase 2.
- Preliminary microbiome analysis confirmed successful engraftment of MaaT033, supporting its safety profile.
- MaaT Pharma plans to analyze the study's overall data by early 2025 to determine next steps, potentially including a larger efficacy study.
Read more
